Home › NCT07680686

Study to Assess How Different Oral Formulations of Ubrogepant Move Through the Body in Healthy Adult Participants

A Two-Part, Phase 1, Open-Label, Randomized Study to Evaluate the Relative Bioavailability (Versus Immediate Release Tablet) and Food Effect of a New Orally Disintegrating Tablet Formulation of Ubrogepant in Healthy Volunteers

Who can join

Ages 18 to 55 · All sexes · Healthy volunteers welcome

Inclusion Criteria:

* BMI is ≥ 18.0 to ≤ 32.0 kg/m2 after rounding to the tenths decimal at Screening. BMI is calculated as weight in kg divided by the square of height measured in meters.
* A condition of general good health, based upon the results of a medical history, physical examination, vital signs, laboratory profile and a 12-lead ECG.

Exclusion Criteria:

* History: of epilepsy, any clinically significant cardiac, respiratory (except mild asthma as a child), renal, hepatic, gastrointestinal, hematologic, neurologic, or psychiatric disease or disorder, history of Raynaud's Phenomenon, or any uncontrolled medical illness.
* History of any clinically significant sensitivity or allergy to any medication or food.

About the study

This study will assess how different oral formulations of ubrogepant move through the body in healthy adult participants under fasting and fed conditions.

What is being tested

• Ubrogepant (drug)
• Ubrogepant (drug)

Sponsor: AbbVie · Participants: 52 · Started: Jul 14, 2026

Contact the study team

• ABBVIE CALL CENTER · Phone: 844-663-3742

Official record on ClinicalTrials.gov — NCT07680686

Locations in the U.S.

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.